Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on ZURA stock, giving a Buy rating on May 9.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Faisal Khurshid’s rating is based on Zura Bio’s strategic advancements and promising developments in their clinical trials. The initiation of the Phase 2 TibuSHIELD trial for tibulizumab in patients with hidradenitis suppurativa (HS) is a significant milestone, demonstrating the company’s timely execution and commitment to advancing its position in the competitive HS landscape. The trial’s design, which includes a randomized placebo-controlled study with a primary assessment period of 16 weeks, aims to provide critical data by the third quarter of 2026.
Additionally, the ongoing Phase 2 TibuSURE trial for systemic sclerosis (SSc) and the anticipated readthrough from Novartis’ ianalumab trial in HS are viewed as relevant catalysts that could potentially de-risk the BAFF hypothesis for tibulizumab. The strong biological rationale for tibulizumab, combined with the company’s strategic positioning amid a crowded competitive field, supports the Buy rating. Management’s clear guidance and the expected data readouts further reinforce confidence in Zura Bio’s potential for growth.
Khurshid covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, aTyr Pharma, and Kymera Therapeutics. According to TipRanks, Khurshid has an average return of 22.7% and a 42.50% success rate on recommended stocks.
In another report released on May 9, Oppenheimer also maintained a Buy rating on the stock with a $17.00 price target.